Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market”, which provides insights into global antibacterial market and market forecast until 2016. The report provides an in-depth analysis of the top seven therapeutic indications for which often antibacterials are prescribed which includes tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media. The report also examines the Global antibacterial treatment usage patterns for the covered indication. In addition, the report also includes insights into the antibacterial R&D pipeline.
Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research analysis shows that the overall global antibacterial market for the seven indications tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media is valued at $11,070m in 2009. The market is expected to witness a growth at a CAGR of 1.5% for the forecast period and will reach $12,160m by 2016. Patent expiries of leading antbacterial, weak pipelines, increase in prevalence and prescription populations and easy availability of generic products are the main reason for growth in antbacterial market. The top pharmaceutical companies in antibacterial market companies - Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCareAG, Johnson & Johnson, Daiichi-Sankyo and Teva pharmaceuticals. Large amount of fragmentation in the market provides significant Scope for consolidation through mergers and acquisitions.
Scope
The Scope of this report includes -
The report will enhance your decision making capability. It will allow you to -
Summary
GBI Research, the leading business intelligence provider, has released its latest research, “Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market”, which provides insights into global antibacterial market and market forecast until 2016. The report provides an in-depth analysis of the top seven therapeutic indications for which often antibacterials are prescribed which includes tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media. The report also examines the Global antibacterial treatment usage patterns for the covered indication. In addition, the report also includes insights into the antibacterial R&D pipeline.
Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research analysis shows that the overall global antibacterial market for the seven indications tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media is valued at $11,070m in 2009. The market is expected to witness a growth at a CAGR of 1.5% for the forecast period and will reach $12,160m by 2016. Patent expiries of leading antbacterial, weak pipelines, increase in prevalence and prescription populations and easy availability of generic products are the main reason for growth in antbacterial market. The top pharmaceutical companies in antibacterial market companies - Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCareAG, Johnson & Johnson, Daiichi-Sankyo and Teva pharmaceuticals. Large amount of fragmentation in the market provides significant Scope for consolidation through mergers and acquisitions.
Scope
The Scope of this report includes -
- Data and analysis on the global antibacterial market.
- Annualized market data for the antibacterial market from 2001 to 2009, with forecasts to 2016.
- Market data on the therapeutic landscape which covers tuberculosis, pneumonia, urinary tract infection, atypical bronchitis, tonsillitis, sinusitis and otitis media, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population and treated population.
- Key drivers and restraints that have had a significant impact on the market and on each indication.
- The competitive landscape of the global anticonvulsant market which includes companies such as Pfizer, Sanofi-Aventis, Abbott, Bayer HealthCare AG, Johnson & Johnson, Daiichi-Sankyo and Teva.
- Key M&A activities and Licensing Agreements that took place from 2005 to 2010 in the global antibacterial market.
The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.
- Device a more tailored country strategy through the understanding of key drivers and barriers of the region’s antibacterial market.
- Develop key strategic initiatives by understanding the key focus areas and top selling antibacterial molecules of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 ANTI-BACTERIALS MARKET TO 2016 – INTRODUCTION
2.1 GBI Research Report Guidance
3 ANTI-BACTERIALS MARKET TO 2016 – OVERVIEW
3.1 Bacterial Classification
3.1.1 Antimicrobial Spectrum
3.1.2 Bacterial Resistance
3.1.3 Cephalosporin Antibiotic
3.1.4 Penicillin Antibiotic
3.1.5 Quinolones Antibiotic
3.1.6 Macrolide Antibiotic
3.2 Antibacterials Market Size
3.2.1 Antibacterial Market Size by Geography
3.2.2 Antibacterial Market Size by indication
3.3 Drivers and Barriers for the Antibacterial Market
3.3.1 Drivers for Antibacterial Market
3.3.2 Barriers for Antibacterial Market
4 ANTI-BACTERIALS MARKET TO 2016 – TUBERCULOSIS
4.1 Overview
4.1.1 Microbiology
4.1.2 Diagnosis
4.1.3 Treatment
4.1.4 Prevention
4.2 Tuberculosis Drugs Market Size
4.3 Tuberculosis Drugs Market Forecast and CAGR
4.4 Drivers and Barriers for Tuberculosis Therapeutics Market
4.4.1 Drivers for the Tuberculosis Drugs Market
4.4.2 Barriers to Tuberculosis Drugs
4.5 Product Profile of the Major Marketed Products in the Tuberculosis Market
4.5.1 Isoniazid (INH)
4.5.2 Rifampin (RIF)
4.5.3 Pyrazinamide (PZA)
4.5.4 Ethambutol (EMB)
4.5.5 Kanamycin
4.5.6 Ofloxacin
4.5.7 Ethionamide
4.6 Global Tuberculosis Market: Pipeline Analysis
4.6.1 Overview
4.6.2 Research and Development Pipeline- Discovery
4.6.3 Research and Development Pipeline – Preclinical
4.6.4 Research and Development Pipeline - Phase I
4.6.5 Research and Development Pipeline - Phase II
4.6.6 Research and Development Pipeline - Phase III
4.7 Global Tuberculosis Market: Strategic Consolidations
4.7.1 Overview
4.7.2 Merger and Acquisition Deals
4.7.3 Research and Development Licensing Agreements
4.7.4 Co-Developments
5 ANTI-BACTERIALS MARKET TO 2016 – PNEUMONIA
5.1 Overview
5.1.1 Microbiology
5.1.2 Diagnosis
5.1.3 Treatment
5.1.4 Prevention
5.2 Pneumonia Drugs Market Size
5.3 Pneumonia Drugs Market Forecast and CAGR
5.4 Drivers and Barriers to Pneumonia Therapeutics Market
5.4.1 Drivers to Pneumonia Drugs market
5.4.2 Barriers to Pneumonia Drugs market
5.5 Product Profile of the Major Marketed Products in the Pneumonia Market
5.5.1 Zyvox (linezolid)
5.5.2 Zosyn (piperacillin and tazobactum)
5.5.3 Levaquin (Levofloxacin)
5.5.4 Avelox (moxifloxacin)
5.5.5 Omnicef (cefnidir)
5.5.6 Tygacil (tigecycline)
5.5.7 Doribax (doripenem)
5.6 Global Pneumonia Therapeutics Market: Pipeline Assessment
5.6.1 Overview
5.6.2 Discovery
5.6.3 Pre-Clinical
5.6.4 Phase I
5.6.5 Phase II
5.6.6 Phase III
5.7 Global Pneumonia Market: Strategic Consolidations
5.7.1 Overview
5.7.2 Merger and Acquisition Deals
5.7.3 Research and Development Licensing Agreements
5.7.4 Co-Developments
6 ANTI-BACTERIALS MARKET TO 2016 – URINARY TRACT INFECTION
6.1 Overview
6.1.1 Microbiology
6.1.2 Diagnosis
6.1.3 Treatment
6.1.4 Prevention
6.2 Urinary Tract Infection Market Size
6.3 Urinary Tract Infections Market Forecast and CAGR
6.4 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market
6.4.1 Drivers for the UTI market
6.4.2 Barriers for the UTI Market
6.5 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market
6.5.1 Doribax (Doripenem)
6.5.2 Ciprofloxacin
6.5.3 Levaquin (levafloxacin)
6.5.4 Monurol (fosfomycin tromethamine)
6.5.5 Macrobid (Nitrofurantoin)
6.5.6 Bactrim/Septra (trimethoprim/sulfamethoxazole)
6.6 Global Urinary Tract Infection Market: Pipeline Assessment
6.6.1 Overview
6.6.2 Discovery
6.6.3 Phase I
6.6.4 Phase II
6.6.5 Phase III
6.7 Global Urinary Tract Infection Therapeutics Market: Strategic Consolidations
6.7.1 Overview
6.7.2 Mergers and Acquisitions Deals
6.7.3 Research and Development Licensing Agreements
6.7.4 Co-Developments
7 ANTI-BACTERIALS MARKET TO 2016 – ATYPICAL BRONCHITIS
7.1 Overview
7.1.1 Microbiology
7.1.2 Diagnosis
7.1.3 Treatment
7.1.4 Prevention
7.2 Atypical Bronchitis Market Size
7.3 Atypical Bronchitis Market Forecast and CAGR
7.4 Drivers and Barriers for Atypical Bronchitis Therapeutics Market
7.4.1 Drivers for atypical Bronchitis
7.4.2 Barriers for Atypical Bronchitis
7.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment
7.5.1 Overview
7.5.2 Phase III
7.6 Global Atypical Bronchitis Therapeutics Market: Strategic Consolidations
7.6.1 Overview
7.6.2 Mergers and Acquisitions Deals
7.6.3 Research and Development Licensing Agreements
7.6.4 Co-Developments
8 ANTI-BACTERIALS MARKET TO 2016 – TONSILLITIS
8.1 Overview
8.1.1 Microbiology
8.1.2 Diagnosis
8.1.3 Treatment
8.1.4 Prevention
8.2 Tonsillitis Market Size
8.3 Tonsillitis Therapeutics Market Forecast and CAGR
8.4 Drivers and Barriers for Tonsillitis Therapeutics Market
8.4.1 Drivers for Tonsillitis
8.4.2 Barriers for Tonsillitis
8.5 Global Tonsillitis Market: Pipeline Assessment
8.5.1 Overview
8.5.2 Research and Development Pipeline - Phase II
8.6 Global Tonsillitis Market: Strategic Consolidations
8.6.1 Overview
8.6.2 Mergers and Acquisitions (M&A) Deals
9 ANTI-BACTERIALS MARKET TO 2016 – SINUSITIS
9.1 Overview
9.1.1 Microbiology
9.1.2 Diagnosis
9.1.3 Treatment
9.1.4 Prevention
9.2 Sinusitis Market Size
9.3 Sinusitis Therapeutics Market Forecast and CAGR
9.4 Drivers and Barriers for Sinusitis Therapeutics Market
9.4.1 Drivers for Sinusitis
9.4.2 Barriers for Sinusitis
9.5 Global Sinusitis Market: Pipeline Assessment
9.5.1 Overview
9.5.2 Pre-Clinical
9.5.3 Phase II
9.5.4 Phase III
9.6 Global Sinusitis Therapeutics Market: Strategic Consolidations
9.6.1 Overview
9.6.2 Mergers and Acquisitions Deals
9.6.3 Research and Development Licensing Agreements
9.6.4 Co-Developments
10 ANTI-BACTERIALS MARKET TO 2016 – OTITIS MEDIA
10.1 Overview
10.1.1 Microbiology
10.1.2 Diagnosis
10.1.3 Treatment
10.1.4 Prevention
10.2 Ottis Media Market Size
10.3 Otitis Media Therapeutics Market Forecast and CAGR
10.4 Drivers and Barriers for Otitis Media Therapeutics Market
10.4.1 Drivers for Otitis Media
10.4.2 Barriers for Otitis Media
10.5 Global Ottis Media: Pipeline Assessment
10.5.1 Overview
10.5.2 Otitis Media – Promising Drugs under Clinical development
10.6 Global Otitis Media Market: Strategic Consolidations
10.6.1 Overview
10.6.2 Mergers and Acquisitions Deals
11 ANTI-BACTERIALS MARKET TO 2016 – COMPANY PROFILES
11.1 Pfizer
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Portfolio
11.1.4 SWOT Profile
11.2 Johnson & Johnson
11.2.1 Overview
11.2.2 Financial performance
11.2.3 Product portfolio
11.2.4 SWOT Profile
11.3 Daiichi-Sankyo
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Portfolio
11.3.4 SWOT Profile
11.4 Bayer HealthCare AG
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Portfolio
11.4.4 SWOT Profile
11.5 Sanofi-Aventis
11.5.1 Overview
11.5.2 Financial performance
11.5.3 Antibacterial Products
11.5.4 SWOT Profile
11.6 Abbott Laboratories
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Portfolio
11.6.4 SWOT Profile
11.7 Teva Pharmaceutical Industries Limited
11.7.1 Overview
11.7.2 Financial performance
11.7.3 Product Portfolio
12 ANTI-BACTERIAL MARKET TO 2016 – APPENDIX
12.1 Market Definition
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research
12.3.4 Forecasting
12.3.5 Expert Panels Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Sources
LIST OF TABLES
Table 1: Antibacterials Therapeutics Market, Classification, Cephalosporin Antibiotics by Generations, 2010
Table 2: Antibacterials Therapeutics Market, Penicillin Antibiotics by Classification, 2010
Table 3: Tuberculosis Therapeutics Market, Global, Revenue ($m), 2001-2009
Table 4: Tuberculosis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 5: Tuberculosis Therapeutics Market, By Region, Revenue ($m), 2001-2009
Table 6: Tuberculosis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016
Table 7: Tuberculosis Therapeutics Market, Global, ACT ($m), 2001-2009
Table 8: Tuberculosis Therapeutics Market, Global, ACT ($m), 2009-2016
Table 9: Tuberculosis Therapeutics Market, Global, Prevalence Population (’000), 2001-2009
Table 10: Tuberculosis Therapeutics Market, Global, Prevalence Population (’000), 2009-2016
Table 11: Tuberculosis Therapeutics Market, Pipeline, Discovery Stage Molecules, 2010
Table 12: Tuberculosis Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2010
Table 13: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Value ($m), 2010
Table 14: Pneumonia Therapeutics Market, Global, Revenue ($m), 2001-2009
Table 15: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 16: Pneumonia Therapeutics Market, By Region, Revenue ($m), 2001-2009
Table 17: Pneumonia Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016
Table 18: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 19: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 20: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (’000), 2001-2009
Table 21: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (’000), 2009-2016
Table 22: Pneumonia Therapeutics Market, Global, Prevalence Population (’000), 2001-2009
Table 23: Pneumonia Therapeutics Market, Global, Prevalence Population (’000), 2009-2016
Table 24: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009
Table 25: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016
Table 26: Pneumonia Therapeutics Market, Global, Diagnosed Population (’000), 2001-2009
Table 27: Pneumonia Therapeutics Market, Global, Diagnosed Population (’000), 2009-2016
Table 28: Pneumonia Therapeutics Market, Global, Prescription Population (’000), 2001-2009
Table 29: Pneumonia Therapeutics Market, Global, Prescription Population (’000), 2009-2016
Table 30: Pneumonia Therapeutics Market, Global, M&A Deals by Value ($m), 2005-2010
Table 31: Pneumonia Therapeutic Market, Global, Licensing Agreements by Value ($m), 2004-2010
Table 32: Pneumonia Therapeutic Market, Global, Co-Developments by Value ($m), 2005-2010
Table 33: Urinary Tract Infection Therapeutics Market, Global, Revenue ($m), 2001-2009
Table 34: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 35: Urinary Tract Infection Therapeutics Market, By Region, Revenue ($m), 2001-2009
Table 36: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 37: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 38: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 39: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009
Table 40: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016
Table 41: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2001-2009
Table 42: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2009-2016
Table 43: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009
Table 44: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016
Table 45: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009
Table 46: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016
Table 47: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2001-2009
Table 48: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2009-2016
Table 49: Urinary Tract Infection Therapeutics Market, Pipeline, Discovery Stage Molecules, 2010
Table 50: Urinary Tract Infection Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 51: Urinary Tract Infection Therapeutics Market, Pipeline, Phase III Molecules, 2010
Table 52: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Value ($m), 2004-2010
Table 53: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Value ($m), 2005-2010
Table 54: Atypical Bronchitis Therapeutics Market, Global, Revenue ($m), 2001-2009
Table 55: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 56: Atypical Bronchitis Therapeutics Market, By Region, Revenue ($m), 2001-2009
Table 57: Atypical Bronchitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016
Table 58: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 59: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 60: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (’000), 2001-2009
Table 61: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (’000), 2009-2016
Table 62: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2001-2009
Table 63: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2009-2016
Table 64: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2001-2009
Table 65: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2009-2016
Table 66: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (‘000), 2001-2009
Table 67: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (‘000), 2009-2016
Table 68: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (’000), 2001-2009
Table 69: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (’000), 2009-2016
Table 70: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Value ($m), 2009-2010
Table 71: Tonsillitis Therapeutics Market, Global, Revenues ($m), 2001-2009
Table 72: Tonsillitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Table 73: Tonsillitis Therapeutics Market, By Region, Revenue ($m), 2001-2009
Table 74: Tonsillitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2009-2016
Table 75: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 76: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 77: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009
Table 78: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016
Table 79: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2009
Table 80: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2009-2016
Table 81: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009
Table 82: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016
Table 83: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009
Table 84: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016
Table 85: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2001-2009
Table 86: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2009-2016
Table 87: Tonsillitis Therapeutics Market, Global, M&A Deals by Value ($m), 2006-2010
Table 88: Sinusitis Therapeutics Market, Global, Revenues ($bn), 2001-2009
Table 89: Sinusitis Therapeutics Market, Global, Revenues Forecasts ($bn), 2009-2016
Table 90: Sinusitis Therapeutics Market, By Region, Revenues ($m), 2001-2009
Table 91: Sinusitis Therapeutics Market, By Region, Revenues Forecasts ($m), 2009-2016
Table 92: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 93: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2009-2016
Table 94: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009
Table 95: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016
Table 96: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2009
Table 97: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2009-2016
Table 98: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009
Table 99: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016
Table 100: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009
Table 101: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016
Table 102: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2001-2009
Table 103: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2009-2016
Table 104: Sinusitis Therapeutics Market, Global, M&A Deals By Value ($m), 2004-2010
Table 105: Sinusitis Therapeutics Market, Global, Licensing Agreements By Value ($m), 2004-2010
Table 106: Otitis Media Therapeutics Market, Global, Revenues ($m), 2001-2009
Table 107: Otitis Media Therapeutics Market, Global, Revenues Forecasts ($m), 2009-2016
Table 108: Otitis Media Therapeutics Market, By Region, Revenues ($m), 2001-2009
Table 109: Otitis Media Therapeutics Market, By Region, Revenues Forecasts ($m), 2009-2016
Table 110: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 111: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2009
Table 112: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2009
Table 113: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2009-2016
Table 114: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2001-2009
Table 115: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2009-2016
Table 116: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2009
Table 117: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2009-2016
Table 118: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2001-2009
Table 119: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2009-2016
Table 120: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2001-2009
Table 121: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2009-2016
Table 122: Otitis Media Therapeutics Market, Pipeline, Preclinical Stage Molecules, 2010
Table 123: Otitis Media Therapeutics Market, Pipeline, Phase II Molecules, 2010
Table 124: Otitis Media Therapeutics Market, Pipeline, Phase III Molecules, 2010
Table 125: Otitis Media Therapeutics Market, Global, M&A Deals, 2009-2010
LIST OF FIGURES
Figure 1: Antibacterials Therapeutics Market, Global, Revenues Forecasts ($m), 2001–2016
Figure 2: Antibacterials Therapeutics Market, Global, Revenue Forecasts ($m), 2001-2016
Figure 3: Antibacterials Therapeutics Market, Global, Revenue Share by Indication (%), 2009
Figure 4: Antibacterials Therapeutics Market, Drivers and Barriers, 2009-2016
Figure 5: Tuberculosis Therapeutics Market, Drugs Used In The Treatment of Tuberculosis, 2010
Figure 6: Tuberculosis Therapeutics Market, Global, Revenue ($m), 2001-2009
Figure 7: Tuberculosis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 8: Tuberculosis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016
Figure 9: Tuberculosis Therapeutics Market, Revenue Share by Geography (%), 2009
Figure 10: Tuberculosis Therapeutics Market, Global, ACT ($m), 2001-2016
Figure 11: Tuberculosis Therapeutics Market, Global, Prevalence Population (’000), 2001-2016
Figure 12: Tuberculosis Therapeutic Market, Market Drivers and Barriers, 2009-2016
Figure 13: Tuberculosis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 14: Tuberculosis Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010
Figure 15: Tuberculosis Therapeutics Market, Global, M&A Deals By Geography (%), 2004-2010
Figure 16: Tuberculosis Therapeutics Market, Global, M&A Deals By Deal Type (%), 2004-2010
Figure 17: Tuberculosis Therapeutics Market, Global, M&A Deals By Year, 2004-2010
Figure 18: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2010
Figure 19: Tuberculosis Therapeutics Market, Global, Licensing Agreements by Year, 2004-2010
Figure 20: Tuberculosis Therapeutics Market, Global, Co-Developments by Geography (%), 2004-2010
Figure 21: Tuberculosis Therapeutics Market, Global, Co-Developments by Year, 2004-2010
Figure 22: Pneumonia Therapeutics Market, Drugs used in the Treatment of Pneumonia, 2010
Figure 23: Pneumonia Therapeutics Market, Global, Revenue ($m), 2001-2009
Figure 24: Pneumonia Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 25: Pneumonia Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016
Figure 26: Pneumonia Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 27: Pneumonia Therapeutics Market, Global, Treatment Usage Patterns (’000), 2001-2016
Figure 28: Pneumonia Therapeutics Market, Global, Prevalence Population (’000), 2001-2016
Figure 29: Pneumonia Therapeutics Market, Global, Treatment Seeking Population (‘000), 2001-2016
Figure 30: Pneumonia Therapeutics Market, Global, Diagnosed Population (’000), 2001-2016
Figure 31: Pneumonia Therapeutics Market, Global, Prescription Population (’000), 2001-2016
Figure 32: Pneumonia Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016
Figure 33: Pneumonia Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 34: Pneumonia Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010
Figure 35: Pneumonia Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010
Figure 36: Pneumonia Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010
Figure 37: Pneumonia Therapeutics Market, Global, M&A Deals by Year, 2004-2010
Figure 38: Pneumonia Therapeutics Market, Global, Licensing Agreements by Geography (%), 2004-2010
Figure 39: Pneumonia Therapeutics Market, Global, Licensing Agreements by Year, 2004-2010
Figure 40: Pneumonia Therapeutics Market, Global, Co-Developments by Geography (%), 2005-2010
Figure 41: Pneumonia Therapeutic Market, Global, Co-Developments by Year, 2005-2010
Figure 42: Urinary Tract Infection Therapeutics Market, Global, Revenue ($m), 2001-2009
Figure 43: Urinary Tract Infection Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 44: Urinary Tract Infection Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016
Figure 45: Urinary Tract Infection Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 46: Urinary Tract Infection Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016
Figure 47: Urinary Tract Infection Therapeutics Market, Global, Prevalence Population (Million), 2001-2016
Figure 48: Urinary Tract Infection Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016
Figure 49: Urinary Tract Infection Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016
Figure 50: Urinary Tract Infection Therapeutics Market, Global, Prescription Population (Million), 2001-2016
Figure 51: Urinary Tract Infection Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016
Figure 52: Urinary Tract Infection Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 53: Urinary Tract Infection Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010
Figure 54: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010
Figure 55: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010
Figure 56: Urinary Tract Infection Therapeutics Market, Global, M&A Deals by Year, 2004-2010
Figure 57: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Geography (%), 2005-2010
Figure 58: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Year, 2005-2010
Figure 59: Urinary Tract Infection Therapeutics Market, Global, Licensing Agreements by Organizations (%), 2005-2010
Figure 60: Atypical Bronchitis Therapeutics Market, Global, Revenue ($m), 2001-2009
Figure 61: Atypical Bronchitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 62: Atypical Bronchitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016
Figure 63: Atypical Bronchitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 64: Atypical Bronchitis Therapeutics Market, Global, Treatment Usage Patterns (’000), 2001-2016
Figure 65: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Prevalence Population (Million), 2001-2016
Figure 66: Atypical Bronchitis Therapeutics Market, Global, Bronchitis Treatment Seeking Population (Million), 2001-2016
Figure 67: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Diagnosed Population (‘000), 2001-2016
Figure 68: Atypical Bronchitis Therapeutics Market, Global, Atypical Bronchitis Prescription Population (’000), 2001-2016
Figure 69: Atypical Bronchitis Therapeutics Market, Market Drivers and Barriers, 2009-2016
Figure 70: Atypical Bronchitis Infection Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010
Figure 71: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010
Figure 72: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010
Figure 73: Atypical Bronchitis Therapeutics Market, Global, M&A Deals by Year, 2004-2010
Figure 74: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Geography (%), 2005-2010
Figure 75: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Year, 2005-2010
Figure 76: Atypical Bronchitis Therapeutics Market, Global, Licensing Agreements by Organizations (%), 2005-2010
Figure 77: Atypical Bronchitis Therapeutics Market, Global, Co-Developments by Geography (%), 2005-2010
Figure 78: Atypical Bronchitis Therapeutics Market, Global, Co-Developments by Year, 2005-2010
Figure 79: Tonsillitis Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 80: Tonsillitis Therapeutics Market, Global, Revenue Forecasts ($m), 2009-2016
Figure 81: Tonsillitis Therapeutics Market, By Region, Revenue Forecasts ($m), 2001-2016
Figure 82: Tonsillitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 83: Tonsillitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016
Figure 84: Tonsillitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2016
Figure 85: Tonsillitis Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016
Figure 86: Tonsillitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016
Figure 87: Tonsillitis Therapeutics Market, Global, Prescription Population (Million), 2001-2016
Figure 88: Tonsillitis Therapeutics Market, Market Drivers and Barriers, 2009-2016
Figure 89: Tonsillitis Therapeutics Market, Global, M&A Deals by Geography (%), 2004-2010
Figure 90: Tonsillitis Therapeutics Market, Global, M&A Deals by Deal Type (%), 2004-2010
Figure 91: Tonsillitis Therapeutics Market, Global, M&A Deals by Year (%), 2004-2010
Figure 92: Sinusitis Therapeutics Market, Global, Revenues ($bn), 2001-2009
Figure 93: Sinusitis Therapeutics Market, Global, Revenues Forecasts ($bn), 2009-2016
Figure 94: Sinusitis Therapeutics Market, By Region, Revenues Forecasts ($m), 2001-2016
Figure 95: Sinusitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 96: Sinusitis Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016
Figure 97: Sinusitis Therapeutics Market, Global, Prevalence Population (Million), 2001-2016
Figure 98: Sinusitis Therapeutics Market, Global, Treatment Seeking Population (million), 2001-2016
Figure 99: Sinusitis Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016
Figure 100: Sinusitis Therapeutics Market, Global, Prescription Population (Million), 2001-2016
Figure 101: Sinusitis Therapeutics Market, Market Drivers and Barriers, 2009-2016
Figure 102: Sinusitis Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 103: Sinusitis Therapeutics Market, Global, Strategic Consolidations (%), 2004-2010
Figure 104: Sinusitis Therapeutics Market, Global, M&A Deals By Geography (%), 2004-2010
Figure 105: Sinusitis Therapeutics Market, Global, M&A Deals By Deal Type (%), 2004-2010
Figure 106: Sinusitis Therapeutics Market, Global, M&A Deals By Year, 2004-2010
Figure 107: Sinusitis Therapeutics Market, Global, Licensing Agreements By Geography (%), 2004-2010
Figure 108: Sinusitis Therapeutics Market, Global, Licensing Agreements By Year (%), 2004-2010
Figure 109: Sinusitis Therapeutics Market, Global, Licensing Agreements By Organizations (%), 2004-2010
Figure 110: Otitis Media Therapeutics Market, Global, Revenues ($m), 2001-2009
Figure 111: Otitis Media Therapeutics Market, Global, Revenues Forecasts ($m), 2009-2016
Figure 112: Otitis Media Therapeutics Market, By Region, Revenues Forecasts ($m), 2001-2016
Figure 113: Otitis Media Therapeutics Market, Global, Annual Cost of Therapy ($), 2001-2016
Figure 114: Otitis Media Therapeutics Market, Global, Treatment Usage Patterns (Million), 2001-2016
Figure 115: Otitis Media Therapeutics Market, Global, Prevalence Population (Million), 2001-2016
Figure 116: Otitis Media Therapeutics Market, Global, Treatment Seeking Population (Million), 2001-2016
Figure 117: Otitis Media Therapeutics Market, Global, Diagnosed Population (Million), 2001-2016
Figure 118: Otitis Media Therapeutics Market, Global, Prescription Population (Million), 2001-2016
Figure 119: Otitis Media Therapeutics Market, Global, Market Drivers and Barriers, 2009-2016
Figure 120: Otitis Media Therapeutics Market, Global, R&D Pipeline by Phase (%), 2010
Figure 121: Otitis Media Therapeutics Market, Global, M&A Deals By Geography (%), 2009-2010
Figure 122: Otitis Media Therapeutics Market, Global, M&A Deals By Deal Type (%), 2009-2010
Figure 123: Otitis Media Therapeutics Market, Global, M&A Deals By Year, 2009-2010
Figure 124: Antibacterial, Pfizer Company Overview, 2010
Figure 125: Antibacterial, Pfizer SWOT Profile, 2010
Figure 126: Antibacterial, Johnson & Johns Skip to top